Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Accumulated Expenses (2016 - 2023)

Historic Other Accumulated Expenses for Aptevo Therapeutics (APVO) over the last 8 years, with Q3 2023 value amounting to $1.3 million.

  • Aptevo Therapeutics' Other Accumulated Expenses rose 1195.56% to $1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.3 million, marking a year-over-year increase of 1195.56%. This contributed to the annual value of $1.1 million for FY2022, which is 4717.16% down from last year.
  • Aptevo Therapeutics' Other Accumulated Expenses amounted to $1.3 million in Q3 2023, which was up 1195.56% from $746000.0 recorded in Q2 2023.
  • Aptevo Therapeutics' Other Accumulated Expenses' 5-year high stood at $2.6 million during Q3 2021, with a 5-year trough of $30000.0 in Q2 2022.
  • Its 5-year average for Other Accumulated Expenses is $1.2 million, with a median of $1.1 million in 2019.
  • As far as peak fluctuations go, Aptevo Therapeutics' Other Accumulated Expenses plummeted by 9696.36% in 2022, and later skyrocketed by 238666.67% in 2023.
  • Aptevo Therapeutics' Other Accumulated Expenses (Quarter) stood at $944000.0 in 2019, then grew by 27.01% to $1.2 million in 2020, then soared by 73.98% to $2.1 million in 2021, then tumbled by 47.17% to $1.1 million in 2022, then rose by 18.97% to $1.3 million in 2023.
  • Its Other Accumulated Expenses stands at $1.3 million for Q3 2023, versus $746000.0 for Q2 2023 and $1.0 million for Q1 2023.